VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AYTU
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AYTUAytu BioPharma, Inc.
$2.66$22M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
AYTU logo

Aytu BioPharma, Inc.

AYTU
NASDAQ · Specialty & Generic Drugs
$2.66
At close - Nov 17, 4:00 PM EST - USD
Market Cap$22M
P/E-2.6x
52W High$3.07
Volume4.32M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Persistent Revenue Contraction Challenges Operational Viability

Aytu BioPharma faces a challenging outlook as its core ADHD and specialty portfolio struggles to maintain market share, evidenced by a revenue decline to $12.4M in 2026Q3 from $18.7M in 2024Q2.

GrowthContracting
ProfitabilityNegative
ValuationAttractive
TechnicalsNeutral
Explore valuation models
MARKET ACTION

AYTU price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

6/12 Beats

EPS beat 6 of last 12 quarters

02

Valuation risk

-110% Peers

P/E is 110% below peer median

03

Market leadership

RS 84 · Leader

High momentum (Outperforming 84% of market)

04

Trend Check

N/A

Trend data unavailable

Next CatalystEstimated earnings · Feb 16

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
AYTU-3.97%
S&P 500 (^GSPC)+7.21%
1-Year Return
AYTU+34.34%
S&P 500 (^GSPC)+10.03%
3-Year Return
AYTU+16.16%
S&P 500 (^GSPC)+115.81%
5-Year Return
AYTU-93.76%
S&P 500 (^GSPC)+92.15%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-2.6x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
16.7%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-2.6x
N/A
N/A
EV/EBITDA
N/A
2.5x
N/A
Price/FCF
6.0x
8.1x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY26
$58M-13.3% YoY
Net income FY26
-$14M-5.1% YoY
Free cash flow FY26
$3M+163.0% YoY
Operating margin FY26
-14.4%-2.7 pts YoY
ROIC (FY26)-32.8%
Avg ROIC 5Y-40%
ROE (TTM)-69.2%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate6/12 (50%)
Revenue Beat Rate10/12 (83%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 16, 2026
-$0.20+22.1%
vs -$0.26
$15M+11.8%
vs $13M
Q4 2026
Sep 22, 2026
-$0.05+82.8%
vs -$0.29
$16M+31.2%
vs $12M
Q2 2026
May 13, 2026
-$0.53-71.0%
vs -$0.31
$12M+3.0%
vs $12M
Q1 2026
Feb 3, 2026
-$1.05-303.8%
vs -$0.26
$15M+24.9%
vs $12M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Benzinga·1d ago
Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket

Shares of Aytu Biopharma Inc (NASDAQ:AYTU) rose sharply in pre-market trading after the pharmaceutical company reported its fiscal 2027 first-quarter results and announced a proposed acquisition by Rosemont Pharmaceuticals.

Zacks Investment Research·1d ago
Aytu BioPharma, Inc. (AYTU) Reports Q1 Loss, Beats Revenue Estimates

Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.08 per share a year ago.

Business Wire·1d ago
AYTU Stock Alert: Halper Sadeh LLC is Investigating Whether Aytu BioPharma, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Aytu BioPharma, Inc. (NASDAQ: AYTU) to Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share.Halper Sadeh encourages Aytu shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether Aytu and its board of directors vio.

GlobeNewsWire·1d ago
Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion

GREENVILLE, S.C. and LEEDS, United Kingdom, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”), a global specialty pharmaceutical company focused on designing and delivering medicines around patients' needs, today announced that it has entered into a definitive merger agreement to acquire Aytu BioPharma, Inc. (“Aytu”) (Nasdaq: AYTU), a US specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases.

Filtered for Aytu BioPharma, Inc.More Headlines
04

Compare before deciding

Benchmark AYTU against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Aytu BioPharma, Inc. (AYTU)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
AYTU logoAYTUAytu BioPharma, Inc.Current
$2.66$21.54M-2.56-13.27%-34.34%-69.19%—
SUPN logoSUPNSupernus Pharmaceuticals, Inc.
$29.04$3.54B7.874.29%32.75%——
TPVG logoTPVGTriplePoint Venture Growth BDC Corp.
$3.70$150.22M6.9155.25%58.87%6.24%27.7%
PRGO logoPRGOPerrigo Company plc
$15.76$2.18B-1.24-2.75%-43.27%-68.13%7.3%
COLL logoCOLLCollegium Pharmaceutical, Inc.
$25.55$828.68M26.1823.62%4.68%12.49%—
JAZZ logoJAZZJazz Pharmaceuticals plc
$240.71$15.12B75.624.88%4.37%4.62%—

Compare AYTU vs Peers

Aytu BioPharma, Inc. (AYTU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SUPN

Most directly comparable listed peer for AYTU.

Scale Benchmark

vs MCK

Larger-name benchmark to compare AYTU against a more recognizable public peer.

Peer Set

Compare Top 5

vs SUPN, TPVG, PRGO, COLL

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

AYTU SEC Filings & Documents

Aytu BioPharma, Inc. (AYTU) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 13, 2026·SEC

Material company update

Apr 2, 2026·SEC

Material company update

Feb 3, 2026·SEC

10-K Annual Reports

3
FY 2025

Sep 23, 2025·SEC

FY 2024

Sep 26, 2024·SEC

FY 2023

Oct 12, 2023·SEC

10-Q Quarterly Reports

6
FY 2026

May 13, 2026·SEC

FY 2026

Feb 3, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when AYTU posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

AYTU Frequently Asked Questions

Aytu BioPharma, Inc. (AYTU) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Aytu BioPharma, Inc.'s revenue?

Aytu BioPharma, Inc. (AYTU) reported $58.5M in revenue over the trailing twelve months. Revenue was $57.6M in fiscal year 2026.

How fast is Aytu BioPharma, Inc. growing?

Aytu BioPharma, Inc. (AYTU) revenue fell by 8.1% over the trailing twelve months, compared with the twelve months before.

Is AYTU profitable?

No. Aytu BioPharma, Inc. (AYTU) reported a net loss of $20.1M over the trailing twelve months.

Dividend & Returns
What is AYTU's return on equity?

Aytu BioPharma, Inc. (AYTU) had a return on equity (ROE) of -69.2% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Aytu BioPharma, Inc.'s free cash flow?

Aytu BioPharma, Inc. (AYTU) generated $3.6M in free cash flow over the trailing twelve months.

What if you invested $1,000 in AYTU back in 2007?

Total return calculator · dividends reinvested · 19+ years of data

See returns →